2019

1. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

   Journal of Clinical Medicine, Vol. 8, Núm. 8

2. The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

   Cancers, Vol. 11, Núm. 11

3. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

   American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899